Women’s Health Market
Description
Size, Share & Trends Analysis Report By Application (Postmenopausal Osteoporosis, Infertility, Endometriosis & Uterine Fibroids), By Drug Class (Hormonal Therapies, Bone Health Agents), By Age, By Region, And Segment Forecasts, 2026 - 2033
Women’s Health Market Summary
The global women’s health market size was estimated at USD 53.48 billion in 2025 and is projected to reach USD 75.42 billion by 2033, growing at a CAGR of 5.1% from 2026 to 2033. Market growth can be attributed to the increase in the geriatric population of women and the introduction of new advanced therapeutic applications for women’s health.
Furthermore, favorable policies initiated by governments to improve women’s health and raise awareness are likely to drive market growth during the forecast period. The market for women s health is increasingly defined by a lifecycle approach that extends beyond reproductive care to include maternal health, fertility, menopause management, and gender specific diagnostics. Governments and multilateral agencies are reinforcing women’s health as a health system priority, influencing regulation, reimbursement, and funding alignment across regions. World Health Organization continues to emphasize sexual and reproductive health and rights as foundational to health system resilience and equity, shaping policy agendas globally.
Regulatory scrutiny has intensified around safety, evidence generation, and inclusion of women across life stages in clinical research, particularly in areas such as hormone therapies and menopause care. This has direct implications for application development strategies, labeling pathways, and post market surveillance requirements. In parallel, healthcare companies are positioning women’s health as a strategic growth and responsibility area within annual reports and investor communications, highlighting increased focus on diagnostics, fertility technologies, and chronic condition management.
Overall, the market is shaped by rising policy engagement, evolving regulatory expectations, and strategic corporate investment, with opportunities centered on evidence backed therapies, diagnostics, and scalable care models aligned with public health priorities.
Global Women’s Health Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global women’s health market report based on application, drug class, age, and region:
Women’s Health Market Summary
The global women’s health market size was estimated at USD 53.48 billion in 2025 and is projected to reach USD 75.42 billion by 2033, growing at a CAGR of 5.1% from 2026 to 2033. Market growth can be attributed to the increase in the geriatric population of women and the introduction of new advanced therapeutic applications for women’s health.
Furthermore, favorable policies initiated by governments to improve women’s health and raise awareness are likely to drive market growth during the forecast period. The market for women s health is increasingly defined by a lifecycle approach that extends beyond reproductive care to include maternal health, fertility, menopause management, and gender specific diagnostics. Governments and multilateral agencies are reinforcing women’s health as a health system priority, influencing regulation, reimbursement, and funding alignment across regions. World Health Organization continues to emphasize sexual and reproductive health and rights as foundational to health system resilience and equity, shaping policy agendas globally.
Regulatory scrutiny has intensified around safety, evidence generation, and inclusion of women across life stages in clinical research, particularly in areas such as hormone therapies and menopause care. This has direct implications for application development strategies, labeling pathways, and post market surveillance requirements. In parallel, healthcare companies are positioning women’s health as a strategic growth and responsibility area within annual reports and investor communications, highlighting increased focus on diagnostics, fertility technologies, and chronic condition management.
Overall, the market is shaped by rising policy engagement, evolving regulatory expectations, and strategic corporate investment, with opportunities centered on evidence backed therapies, diagnostics, and scalable care models aligned with public health priorities.
Global Women’s Health Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global women’s health market report based on application, drug class, age, and region:
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Hormonal Infertility
- Contraceptives
- Postmenopausal Osteoporosis
- Endometriosis & Uterine Fibroids
- Menopause
- Polycystic Ovary Syndrome (PCOS)
- Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
- Hormonal Therapies
- Bone Health Agents
- Fertility Agents
- GnRH Modulators
- Pain and Symptom Management
- Metabolic Agents
- Others
- Age Outlook (Revenue, USD Million, 2021 - 2033)
- 50 years and above
- Postmenopausal Osteoporosis
- Endometriosis & Uterine Fibroids
- Menopause
- Others
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Application
- 1.2.2. Drug Class
- 1.2.3. Age
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR’s Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Women’s Health Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter’s Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- Chapter 4. Women’s Health Market: Application Business Analysis
- 4.1. Application Market Share, 2025 & 2033
- 4.2. Application Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 4.4. Hormonal Infertility
- 4.4.1. Hormonal Infertility Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Contraceptives
- 4.5.1. Contraceptives Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Postmenopausal Osteoporosis
- 4.6.1. Postmenopausal Osteoporosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.7. Endometriosis & Uterine Fibroids
- 4.7.1. Endometriosis & Uterine Fibroids Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.8. Menopause
- 4.8.1. Menopause Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.9. Polycystic Ovary Syndrome (PCOS)
- 4.9.1. Polycystic Ovary Syndrome (PCOS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 5. Women’s Health Market: Drug Class Business Analysis
- 5.1. Drug Class Market Share, 2025 & 2033
- 5.2. Drug Class Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
- 5.4. Hormonal Therapies
- 5.4.1. Hormonal Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Bone Health Agents
- 5.5.1. Bone Health Agents Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6. Fertility Agents
- 5.6.1. Fertility Agents Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.7. GnRH Modulators
- 5.7.1. GnRH Modulators Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.8. Pain and Symptom Management
- 5.8.1. Pain and Symptom Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.9. Metabolic Agents
- 5.9.1. Metabolic Agents Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.10. Others
- 5.10.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 6. Women’s Health Market: Age Business Analysis
- 6.1. Age Market Share, 2025 & 2033
- 6.2. Age Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 6.4. 50 years and above
- 6.4.1. 50 years and above Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.2. Postmenopausal Osteoporosis
- 6.4.2.1. Postmenopausal Osteoporosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.3. Endometriosis & Uterine Fibroids
- 6.4.3.1. Endometriosis & Uterine Fibroids Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.4. Menopause
- 6.4.4.1. Menopause Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.5. Others
- 6.4.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Others
- 6.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 7. Women’s Health Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2025 & 2033
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 7.4. North America
- 7.4.1. North America Women’s Health Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Type Disease Prevalence
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. Reimbursement Framework
- 7.4.2.5. U.S. Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Type Disease Prevalence
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Reimbursement Framework
- 7.4.3.5. Canada Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Type Disease Prevalence
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. Reimbursement Framework
- 7.4.4.5. Mexico Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Europe
- 7.5.1. Europe Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Type Disease Prevalence
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Reimbursement Framework
- 7.5.2.5. Uk Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Type Disease Prevalence
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. Reimbursement Framework
- 7.5.3.5. Germany Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Type Disease Prevalence
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. Reimbursement Framework
- 7.5.4.5. France Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Type Disease Prevalence
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Reimbursement Framework
- 7.5.5.5. Italy Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Type Disease Prevalence
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Reimbursement Framework
- 7.5.6.5. Spain Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Type Disease Prevalence
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Reimbursement Framework
- 7.5.7.5. Denmark Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Type Disease Prevalence
- 7.5.8.3. Regulatory Framework
- 7.5.8.4. Reimbursement Framework
- 7.5.8.5. Sweden Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Type Disease Prevalence
- 7.5.9.3. Regulatory Framework
- 7.5.9.4. Reimbursement Framework
- 7.5.9.5. Norway Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Type Disease Prevalence
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Reimbursement Framework
- 7.6.2.5. Japan Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Type Disease Prevalence
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. Reimbursement Framework
- 7.6.3.5. China Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Type Disease Prevalence
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. Reimbursement Framework
- 7.6.4.5. India Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Type Disease Prevalence
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Reimbursement Framework
- 7.6.5.5. Australia Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Type Disease Prevalence
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. Reimbursement Framework
- 7.6.6.5. South Korea Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Type Disease Prevalence
- 7.6.7.3. Regulatory Framework
- 7.6.7.4. Reimbursement Framework
- 7.6.7.5. Thailand Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Type Disease Prevalence
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. Reimbursement Framework
- 7.7.2.5. Brazil Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Type Disease Prevalence
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Reimbursement Framework
- 7.7.3.5. Argentina Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Type Disease Prevalence
- 7.8.2.3. Regulatory Framework
- 7.8.2.4. Reimbursement Framework
- 7.8.2.5. South Africa Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Type Disease Prevalence
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. Reimbursement Framework
- 7.8.3.5. Saudi Arabia Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Type Disease Prevalence
- 7.8.4.3. Regulatory Framework
- 7.8.4.4. Reimbursement Framework
- 7.8.4.5. UAE Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Type Disease Prevalence
- 7.8.5.3. Regulatory Framework
- 7.8.5.4. Reimbursement Framework
- 7.8.5.5. Kuwait Women’s Health Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. AbbVie, Inc.
- 8.5.1.1. Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Application Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. Bayer AG
- 8.5.2.1. Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Application Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Organon & Co.
- 8.5.3.1. Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Application Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. Pfizer, Inc.
- 8.5.4.1. Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Application Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. Agile Therapeutics
- 8.5.5.1. Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Application Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. Amgen, Inc.
- 8.5.6.1. Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Application Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. Apothecus Pharmaceutical Corp.
- 8.5.7.1. Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Application Benchmarking
- 8.5.7.4. Strategic Initiatives
- 8.5.8. Blairex Laboratories, Inc.
- 8.5.8.1. Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Application Benchmarking
- 8.5.8.4. Strategic Initiatives
- 8.5.9. Ferring
- 8.5.9.1. Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Application Benchmarking
- 8.5.9.4. Strategic Initiatives
- 8.5.10. Theramex
- 8.5.10.1. Overview
- 8.5.10.2. Financial Performance
- 8.5.10.3. Application Benchmarking
- 8.5.10.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
